NCT06351592

Who might be able to join this trial:

• You have muscle weakness caused by ALS, and genetic testing has shown you carry a change in the SOD1 gene that is known or likely to cause ALS
• Your lungs are working at 50% or more of the expected level for someone your age, sex, and height (measured while sitting or standing upright)
• Your Body Mass Index (BMI) — a measure of body weight relative to height — is 35 or below at the time of your screening appointment
• If you are currently taking riluzole or edaravone (common ALS medicines), you have been on a stable, unchanged dose for at least 4 weeks before starting the trial and are expected to stay on that dose throughout the study
• Your blood platelet count (cells that help blood clot) is above 50,000 per microliter of blood
• Your blood pressure readings are within a normal range, as defined by the trial guidelines

Who may not be able to join:

• You are currently taking part in another clinical trial that involves a treatment or intervention
• You have previously had a tracheostomy (a surgical opening in the throat to help with breathing)
• You have been diagnosed with dementia, as assessed by the trial doctor
• You have had uncontrolled mental health conditions — such as psychosis, thoughts of suicide, or untreated major depression — in the past 30 days
• You have a history of brain or spinal disease or injury that could interfere with a lumbar puncture (spinal tap) procedure or affect safety assessments (confirm with trial site)
• You have an implanted device that drains fluid from around the brain or spinal cord, or a catheter implanted in the central nervous system
• The trial doctor has any other concern that your participation could affect the study results or put you at additional risk
• You were admitted to hospital for more than 24 hours for any reason other than ALS within 30 days before your screening appointment
• You have received a treatment called tofersen within the 6 months before your screening appointment

Important: Always verify eligibility with the trial site directly before applying.